01—Abstract
Summary
Summary of the 10-Q filed July 31, 2026. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific Inc. (TMO) reported strong financial results for the quarter and six months ended June 27, 2026, demonstrating robust revenue growth and improved profitability.
Total revenues increased by 10%a in the quarter and 8% for the year-to-date period, driven by strong performance across its diverse business segments, particularly Life Sciences Solutions and Laboratory Products and Biopharma Services. The company saw significant contributions from recent acquisitions, notably Clario Holdings, Inc., which bolstered its clinical research offerings. Profitability metrics also showed improvement, with GAAP operating income up 14% for the quarter and adjusted operating income margin expanding by 90 basis points.
This growth was attributed to strong productivity improvements, successful integration of acquisitions, and favorable market conditions in key end markets like pharmaceutical and biotech. The company's strategic focus on innovation, customer partnerships, and its commercial engine continues to yield positive results, positioning Thermo Fisher for sustained growth.
02—Key points
Key Highlights
- Total revenues increased by 10% to $11.99 billion for the three months ended June 27, 2026, and by 8% to $22.99 billion for the six months ended June 27, 2026, compared to the prior year periods.
- GAAP operating income grew by 14% to $2.09 billion for the three months and 11% to $3.95 billion for the six months, while adjusted operating income margins expanded, indicating strong operational efficiency.
- The Life Sciences Solutions segment reported a 13% revenue increase for the quarter, driven by strong demand in bioproduction, and a 13% increase for the six months.
- The Laboratory Products and Biopharma Services segment saw a 12% revenue increase for the quarter and 9% for the six months, significantly boosted by the acquisition of Clario Holdings, Inc.
- The company repurchased $4.00 billion of its common stock in the first six months of 2026 under its authorized share repurchase program, demonstrating a commitment to returning capital to shareholders.
- Free cash flow generation remained strong, with $2.50 billion generated in the first six months of 2026, up from $1.48 billion in the prior year period, supporting capital allocation strategies.
- The company announced an agreement to sell its microbiology business to Astorg for approximately $1.075 billion, expected to close in the third quarter of 2026, indicating strategic portfolio management.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2026filed July 31, 2026Financial Statements
Q2 FY2026 against Q2 FY2025
| Line item | Q2 FY2026Q2 FY2025 | Change |
|---|---|---|
| Revenue | $11.99B$10.86B | +10.5% |
| R&D Expenses | $364.00M$352.00M | +3.4% |
| SG&A Expenses | $2.33B$2.14B | +9.0% |
| Operating Expenses | $9.91B$9.02B | +9.8% |
| Operating Income | $2.09B$1.83B | +13.8% |
| Net Income | $1.74B$1.62B | +7.6% |
| EPS (Basic) | $4.68$4.28 | +9.3% |
| EPS (Diluted) | $4.68$4.28 | +9.3% |
| Shares Outstanding (Basic) | 371.00M378.00M | −1.9% |
| Shares Outstanding (Diluted) | 371.00M378.00M | −1.9% |
05—Questions
Frequently Asked Questions
What is the overall financial performance of Thermo Fisher Scientific in this reporting period?
Thermo Fisher Scientific demonstrated strong financial performance, with total revenues increasing by 10% to $11.99 billion for the three months ended June 27, 2026, and by 8% to $22.99 billion for the six months ended June 27, 2026. Profitability also improved, with GAAP operating income up 14% for the quarter and adjusted operating income margin expanding, reflecting strong operational execution and productivity improvements.
How did the recent acquisitions impact the company's performance?
Recent acquisitions, particularly Clario Holdings, Inc. in the Laboratory Products and Biopharma Services segment, have had a significant positive impact on revenue growth. The integration of Clario expanded the company's clinical research offerings and contributed substantially to the segment's revenue increase. The acquisition of the filtration and separation business from Solventum Corporation also bolstered the Life Sciences Solutions segment.
What is the outlook for the company's cash flow and capital allocation?
The company generated strong free cash flow, with $2.50 billion in the first six months of 2026, supporting its capital allocation priorities. These priorities include strategic acquisitions, share repurchases (with $4.00 billion repurchased in the first six months of 2026), and dividend payments. The company expects its existing cash, future operating cash flow, and available credit facilities to be sufficient to meet its cash requirements for at least the next 24 months.
Are there any significant divestitures or portfolio changes being made?
Yes, Thermo Fisher Scientific has entered into an agreement to sell its microbiology business to Astorg for approximately $1.075 billion, which is expected to close in the third quarter of 2026. This divestiture suggests a strategic focus on core business areas and portfolio optimization.
06—Continue